Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma
Anna Imiela, Jakub Surmacki, Halina Abramczyk
Abstract
We developed a label-free Raman method for monitoring the therapeutic benefit of temozolomide in glioblastoma by whole-cell biochemical hyperspectral imaging for detecting molecular processes occurring in normal and tumorous brain cells at the level of isolated organelles. Our approach allows biochemical compositional mapping of lipid droplets, mitochondria, and nucleus in single cells, monitoring intracellular alterations upon using different doses of temozolomide, a drug normally used to treat gliomas. We detected Raman spectral changes in DNA, proteins and lipids. The viability (% of control) of high grade tumorous cells of glioblastoma U87MG after incubation for 24 and 48 h with temozolomide has been measured. The Raman spectral changes in separate organelles of glioblastoma cells helps to elucidate the detailed mechanisms of action of temozolomide.